Adjudicated US Private
Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos
Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.
CASE PROFILE & BENCHMARKS
- Target Issuer: Theranos, Inc. (US).
- Fraud Period: January 1, 2018 to December 31, 2020.
- Reported Overstatement: $700.0M.
- Total Fines & Penalties: $500K.
- Maximum Incarceration: No prison sentence.
- Independent Auditor: PricewaterhouseCoopers LLP.
- Primary Schemes: misleading non gaap and kpis.
- Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $700.0M USD reported
TOTAL PENALTIES $500K Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2020 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR U.S. Securities and Exchange Commission US
FORENSIC ACCOUNTING AUTOPSY & MECHANICS
COMPREHENSIVE MULTI-PHASE INVESTIGATION| Forensic Dimension | Investigative Finding & Evidentiary Record |
|---|---|
| Executive Motive & Pressure | Founded by Elizabeth Holmes in 2003, Theranos raised over $900M from high-profile investors at a $9B valuation by claiming its 'Edison' and 'miniLab' devices could run hundreds of clinical blood tests from a single finger-prick drop. |
| Auditor Blind Spots & Breakdown | As a private company, Theranos operated without an independent public-company PCAOB audit for most of its growth phase, utilizing strict NDAs, compartmentalized labs, and selective investor demonstrations to prevent technical and financial due diligence. |
| Detection Catalyst & Unraveling | In October 2015, Wall Street Journal investigative reporter John Carreyrou exposed that Theranos ran almost all blood tests on commercial Siemens machines rather than its own Edison box. CMS regulators subsequently revoked Theranos's lab license, leading to SEC fraud charges and criminal wire fraud convictions for Holmes and Balwani. |
| Screening & Prevention Takeaway | Private Valuation Governance & Unaudited Projections: Extreme secrecy, refusal to publish peer-reviewed validation, and lack of independent audited financial statements at multi-billion-dollar private valuations are critical red flags for institutional due diligence. |
| Statutory Violations & Charges | 18 U.S.C. Section 1343 & 1349 (Wire Fraud & Conspiracy to Commit Wire Fraud) Securities Act Section 17(a) & Exchange Act Section 10(b) CMS Clinical Laboratory Improvement Amendments (CLIA) License Revocation |
STEP-BY-STEP SCHEME EXECUTION MECHANICS
4 PHASES| Phase | Execution Step & General Ledger Mechanics |
|---|---|
| Step 01 | 1. Theranos's proprietary finger-prick devices failed internal accuracy benchmarks on most assays, so lab staff secretly diluted finger-prick samples and ran them on modified commercial Siemens analyzers. |
| Step 02 | 2. Holmes and COO Sunny Balwani presented investors with fabricated financial models projecting $100M in 2014 revenue and $1B in 2015 revenue when actual commercial lab revenue was near zero. |
| Step 03 | 3. Marketing decks displayed logos of major pharmaceutical companies (Pfizer, GlaxoSmithKline) as active validators even though those firms had declined partnerships. |
| Step 04 | 4. Executives falsely claimed the US military was actively deploying Theranos devices on medevac helicopters in Afghanistan. |
FORENSIC JOURNAL ENTRIES & T-ACCOUNT DISTORTIONS
GENERAL LEDGER TRANSACTIONS| Period | Debit (+) Account | Debit ($) | Credit (-) Account | Credit ($) | Forensic Intent & Financial Statement Distortion |
|---|---|---|---|---|---|
| 2013-2015 (Investor Private Placement Misrepresentation) | Cash (Series C-1 / C-2 Venture Proceeds) | $700.0M | Preferred Equity Capital (Raised on False Revenue Models) | $700.0M | Intent: Raise $700M+ from private investors using fabricated $100M-$1B revenue projections and fake DoD contract claims. Distortion: Values private shares at $9B despite less than $100,000 in genuine commercial diagnostic revenue. |
| Taxonomy | Applicable Scheme Classifications |
|---|---|
| Correlated Schemes |
CHARGED RESPONDENTS & OUTCOMES
1 NAMED PARTIES| Respondent | Role | Disposition & Judicial Outcome | Prison | Civil Penalty | O&D Bar |
|---|---|---|---|---|---|
| Theranos, Inc. | ISSUER | Enforcement order and financial sanctions imposed. | None | $500K | No |
RED FLAGS OBSERVED PRIOR TO DISCOVERY
1 EARLY WARNING INDICATORS| Red Flag Indicator | Period Observed | Observed Forensic Anomaly | Diagnostic View |
|---|---|---|---|
| CASH FLOW TO NET INCOME DIVERGENCE | 2018 | Operating cash flow severely diverged from reported earnings | Inspect Metric → |
ENFORCEMENT ACTIONS & PRIMARY DOCKETS
PRIMARY SOURCE CITATIONS| Filing Date | Type & Docket ID | Enforcement Order & Regulatory Findings | Disposition | Primary Record |
|---|---|---|---|---|
| September 20, 2020 | aaer ENF-2018-theranos | Enforcement Action: Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines. Securities & Corporate Law Compliance
Source: U.S. Securities and Exchange Commission: Accounting and Auditing Enforcement Releases (AAER) • Official Jurisdiction: US | admitted | Docket Record ↗ |
TIMELINE OF EVENTS
2 CHRONOLOGICAL MILESTONES| Date | Event Category | Chronological Forensic Milestone |
|---|---|---|
| June 1, 2018 | MISSTATEMENT | Material accounting irregularities commenced. |
| September 20, 2020 | ENFORCEMENT | Regulators commenced formal proceedings. |